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ABSTRACT.
Mechanisms underlying the opposite effects of TM6SF2 rs58542926 C>T polymorphism on liver injury and cardio-metabolic risk in NAFLD are unclear. We assessed the impact of this polymorphism on postprandial lipoprotein metabolism, glucose homeostasis, and nutrient oxidation in NAFLD.
Sixty nonobese, nondiabetic, normolipidemic biopsy-proven NAFLD patients and 60 matched controls genotyped for TM6SF2 C>T polymorphism underwent: indirect calorimetry, an oral fat tolerance test with measurement of plasma lipoprotein subfractions, adipokines, incretin GIP, and an OGTT with Minimal Model analysis of glucose homeostasis.
TM6SF2 T-allele was associated with higher hepatic and adipose insulin resistance, with impaired pancreatic ß-cell function and incretin effect and with higher muscle insulin sensitivity and whole-body fat oxidation rate.
Compared with TM6SF2 C-allele, T-allele entailed lower postprandial lipemia and nefaemia, a less atherogenic lipoprotein profile, a postprandial cholesterol redistribution from smaller, atherogenic lipoprotein subfractions to larger intestinal and hepatic VLDL1 subfration. Postprandial plasma VLDL1-cholesterol response independently predicted the severity of liver histology.
In conclusion, TM6SF2 C>T polymorphism affects nutrient oxidation, glucose homeostasis, and postprandial lipoprotein, adipokine and GIP responses to fat ingestion, independently of fasting values. These differences may contribute to the dual and opposite effect of this polymorphism on liver injury and cardio-metabolic risk in NAFLD.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) confers an increased risk of liver-related complications (largely limited to its progressive form, non-alcoholic steatohepatitis, NASH), of type 2 diabetes (T2DM), and of cardiovascular disease (CVD) [1, 2] . The wide inter-individual variability in the risk of hepatic and extra-hepatic complications in NAFLD may reflect the interplay between genetic and environmental factors. While in the general population an association between the type and amount of dietary fat and the development of obesity, CVD and T2DM has been demonstrated [3] ,data linking dietary fat to the presence and severity of NAFLD are controversial [4, 5] .We hypothesized a genetically determined susceptibility to dietary fat lipotoxicity modulates liver injury and cardio-metabolic risk in NAFLD.
The single nucleotide polymorphism (SNP) rs58542926 C>T in the Transmembrane 6 superfamily member 2 gene (TM6SF2) has been recently linked to the severity of NAFLD in genome-wide association studies (GWAS) [6, 7] : TM6SF2 T-allele, encoding the E167K aminoacidic substitution, results in reduced transcript levels of its product protein, which is expressed in humans in the liver, intestine, adipose tissue and pancreatic -cells and has unclear biological function [8, 9] .
TM6SF2 C>T variant has been linked to a reduced LDL-cholesterol level and cardiovascular risk and to an increased risk of type 2 diabetes [10, 11] . Mechanisms connecting TM6SF2 C>T polymorphism to liver injury and cardio-metabolic risk are unclear. The impaired hepatic VLDL secretion associated with TM6SF2 T-allele [8, 9] may not be the main mechanism mediating NASH, as enhanced lipid storage into neutral triglycerides protects against liver injury [12] . Furthermore, the reduced CVD risk associated with TM6SF2 T-allele is not fully explained by lower fasting cholesterol levels [13] . Postprandial lipemia is an emerging cardio-metabolic risk factor, independently of fasting lipid levels [14] , and dietary fat lipotoxicity has been implicated in liver injury in NASH [3, 4, 5] : Hypothesizing dietary fat lipotoxicity may mediate the impact of TM6SF2 on liver disease and cardio-metabolic risk in NAFLD, we assessed the effect of TM6SF2 C>T variant on postprandial lipoprotein metabolism and on glucose homeostasis in biopsy-proven NAFLD patients and healthy controls.
METHODS
Participants. There are no data on the impact of TM6SF2 C>T variant on postprandial lipoprotein metabolism and glucose homeostasis. Based on available data on the impact of TM6SF2 C>T variant on fasting lipid levels [6, 7, 8, 10 ] and on the impact of NAFLD on lipoprotein and glucose metabolism [12, 15] , considering a type I error of 0.05 and a type II error of 0.20: at least 18 T-allele carriers per arm were needed to detect a significant difference in parameters related to lipoprotein metabolism (IAUC triglyceride and LDL-C) and glucose homeostasis (whole-body and tissue insulin sensitivity, β-cell function) within different TM6SF2 genotypes in NAFLD patients.
As obesity, dyslipidemia and diabetes may modify the effect of TM6SF2 C>T variant on glucose/lipid metabolism, on adipokines and on liver disease, subjects with obesity(BMI ≥30 kg/m2), diabetes(fasting plasma glucose 126 mg/dl or plasma glucose 200 mg/dL at +2h on OGTT or antidiabetic drugs), overt dyslipidaemia(fasting serum cholesterol ≥ 200 mg/dL or plasma triglyceride ≥ 200 mg/dL) or clinical signs/symptoms of CVD were excluded.
Sixty nonobese nondiabetic normolipidemic biopsy-proven NAFLD patients referred to two Hepato-Metabolic Clinics were included (criteria for diagnosis of NAFLD are detailed in Supplementary Online Appendix). Each pathological feature of liver biopsy was read by a single pathologist (RP) blinded to the patient clinical-biochemical characteristics and scored according to the NASH Clinical Research Network criteria; NASH was defined according to current recommendations [1] .
Sixty randomly identified healthy controls, i.e. nondiabetic nonobese normolipidemic individuals without evidence of CVD, randomly selected from a population-based cohort study, matched for TM6SF2 C>T genotype, age, gender, BMI, and waist circumference were included [12] . Criteria to rule out NAFLD in controls are detailed in Supplementary Online Appendix.
Patients and controls were characterized for lifestyle habits, routine biochemistry, adipokine profile, markers of inflammation and endothelial dysfunction, as detailed below. Homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated as the product of the fasting glucose and insulin concentration divided by 22.5[16].
Participants gave their consent to the study, which was conducted according to the Helsinki Declaration and was approved by the Institutional Review Board of San Giovanni Battista Hospital, Turin, Italy
Genetic analyses.
Genotyping for TM6SF2 rs58542926 C/T SNP utilized the real-time allele discrimination method, using TaqMan Allelic Discrimination Assay (Applied Biosystems, Foster city, CA). The TaqMan genotyping reaction was run on an 7300HT Fast Real-Time PCR (Applied Biosystem).
We also genotyped our population for the PNPLA3 SNP rs738409 C/G and for apoE genotype, which have been previously linked to both NAFLD and lipid metabolism [17] , to assess their interference with outcome variables (detailed in Supplementary Online Appendix).
Dietary and physical activity record.
Participants filled in the validated European Prospective Investigation into Cancer and Nutrition (EPIC) 7-day alimentary questionnaire, and the Minnesota-Leisure-Time-Physical-Activity questionnaire, and data were analyzed as described in Supplementary Online Appendix.
Anthropometry.
Percent body fat was estimated by the bioelectrical impedance analysis (BIA) method (TBF-202, Tanita, Tokyo, Japan), closely correlating with dual X ray absorption [ Incretin effect. To assess if differences in -cell function were related to a reduced incretin stimulatory effect on -cell, a FIVGTT was performed and the incretin effect, i.e., the effectiveness of ingested glucose in stimulating -cell insulin secretion compared to intravenous. glucose, was assessed (see Supplementary online Appendix).
Oral fat tolerance test (OFTT).
Participants underwent a 10-hour oral fat tolerance test(OFTT) Plasma GIP, as well as resistin and adiponectin, which have been linked to both liver disease severity and lipoprotein metabolism in NAFLD, were measured as detailed in
Supplementary Online Appendix.
Statistical analysis
Differences across groups were analyzed by ANOVA followed by Bonferroni correction, when variables were normally distributed; otherwise the Kruskal-Wallis test, followed by the post hoc Dunn test, was used. Normality was evaluated by Shapiro-Wilk test. Fisher or chi-square test were used to compare categorical variables, as appropriate. HardyWeinberg equilibrium was assessed using 2 test.
To adjust for multiple comparison testing, the Benjamini-Hochberg False Discovery Rate correction was applied to raw p-values in all comparisons; significance was set at an When a relation was found on univariate analysis, multivariate logistic regression was used to identify independent predictors of selected outcome variables of interest, namely:
-for liver histology: the presence of NASH and of advanced (stage 3) fibrosis -for CVD risk: serum CRP and endothelial adhesion molecules E-selectin and ICAM-1;
-for whole-body nutrient oxidation rates: CHO ox and fat ox .
-for glucose homeostasis: OGTT-derived parameters of whole-body/tissue insulin resistance and of β-cell function;
-for postprandial lipid metabolism: the IAUC of triglyceride, LDL-C, oxLDL and of of main triglyceride-rich lipoprotein subfractions.
For this analysis, continuous variables were divided into quartiles and independent predictors of the highest quartile of outcome variable were asesssed, after after log transformation of skewed data. The independent predictors were those variables found to be related to the outcome variables on univariate analysis.
Data were expressed as mean ± SEM, unless otherwise specified. (STATISTICA software, 5.1, Statsoft Italia, Padua, Italy)
RESULTS.

Subjects characteristics
Main features of patients and controls grouped according to TM6SF2 C>T genotype are reported in Table 1 .
In study participants, the prevalence TM6SF2 CC homozygotes was 64%, of CT heterogygotes was 34%, of TT carriers was 2%;
The distribution of TM6SF2 CT genotype was in Hardy-Weinberg equilibrium(6, 7, 8).
NAFLD as a group had higher HOMA, serum CRP and endothelial adhesion molecules E-selectin and ICAM-1 and lower HDL-C and adiponectin than controls. Within NAFLD patients and controls, TM6SF2 CT/TT carriers showed lower serum CRP and endothelial adhesion molecules than TM6SF2 CC genotype carriers ( Table 1) .
Among NAFLD patients, 42% had NASH and 16% had advanced fibrosis. TM6SF2 Tallele carriers had more severe liver histology than their counterpart genotype ( Table 1) .
Alimentary record.
There was no difference in daily total energy, macro-and micro-nutrient, types of fat and antioxidant vitamin intake between patients with NAFLD and controls and among different TM6SF2 genotypes (not shown).
Indirect calorimetry.
While TM6SF2 C>T variant did not affect REE, the proportion of energy derived from fat and CHO oxidation differed between TM6SF2 genotypes: TM6SF2 T-allele carriers had lower RQ and npRQ, indicating they oxidize more fat and less CHO that CC homozygotes( Table 1) .
OGTT-derived indexes of glucose homeostasis
The time course of plasma glucose and serum insulin during the OGTT is reported in Figure S1 . In patients and controls, TM6SF2 T-allele carriers showed higher hepatic and adipose insulin resistance but enhanced muscle insulin sensitivity than CC homozygotes TM6SF2 CT/TT genotype displayed also impaired pancreatic β-cell function and incretin effect than CC homozygotes( Table 2) .
Oral fat tolerance test. 1.14-2.59, p=0.002). and IAUC GIP (β=0.49, 95%CI: 0.18-0.88, p=0.012).
Independent predictors of outcome variables on multiple logistic regression analysis
The independent determinants of OGTT-related glucose homeostasis parameters and of posptrandial lipoprotein and adipokine responses during oral tat tolerance test are reported in Table 4 .
DISCUSSION
The main findings of our study are the following: An intriguing finding was the impact of TM6SF2 SNP on muscle insulin sensitivity and whole-body fat oxidation rates, both effects related to postprandial adiponectin and GIP responses to fat ( Table 4) .
Consistent with our data, adiponectin stimulates muscle fat oxidation and insulin sensitivity, while GIP potently reduces energy expenditure and fat oxidation [39] . The link between TM6SF2 and incretins and the role of GIP antagonism to enahnce fat oxidation and insulin sensitivity warrant future investigation. In the meantime, it should be noted that GIP increase induced by dipeptidyl peptidase-IV (DDP-IV) inhibitors, currently evaluated in NAFLD, may attenuate the benefits of glucagon-like peptide(GLP)1 elevation [40] .
In conclusion, a maladaptive response to a chronic, daily, repetitive metabolic challenge A further caveat is that we did not measure directly hepatic and muscle insulin sensitivity but rather estimated them from the time course of glucose and insulin during the OGTT.
This method assumes a similar intestinal glucose absorption rate across TM6SF2 genotypes, as a faster glucose absorption rate in TM6SF2 T-allele carriers would cause a steeper increase and an earlier peak and fall in plasma glucose regardless of any actual differences in tissue insulin sensitivity: however, the visual inspection of plasma glucose curve during the OGTT (Supplementary Figure S1) shows a similar slope in the 0'-30' ascending limb of the curve across TM6SF2 genotypes and the same peak time (+60'), making differences in glucose absorption very unlikely to occur.
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